LAVA Therapeutics N.V. Files Proxy Statement
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | DEFA14A |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $1.16, $0.08 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, governance
TL;DR
LAVA Therapeutics filed its proxy statement, shareholders vote soon.
AI Summary
LAVA Therapeutics N.V. filed a Definitive Proxy Statement (DEFA14A) on August 15, 2025, related to its annual shareholder meeting. The filing indicates no fee was required for this submission. The company is incorporated in P7 with its fiscal year ending on December 31st.
Why It Matters
This filing is a standard regulatory requirement for public companies to inform shareholders about upcoming meetings and matters to be voted upon, ensuring corporate governance transparency.
Risk Assessment
Risk Level: low — This is a routine regulatory filing for a public company and does not contain new financial or operational information that would inherently increase risk.
Key Players & Entities
- LAVA Therapeutics N.V. (company) — Registrant
- 0001104659-25-079244 (filing_id) — Accession Number
- 20250815 (date) — Filing Date
- 0001840748 (company_id) — Central Index Key
- 2834 (sic_code) — Standard Industrial Classification
- P7 (state) — State of Incorporation
- 1231 (fiscal_year_end) — Fiscal Year End
- DEFA14A (form_type) — Filing Type
- 1934 Act (regulation) — SEC Act
- 001-40241 (sec_file_number) — SEC File Number
FAQ
What type of filing is this?
This is a Definitive Proxy Statement (DEFA14A) filed by LAVA Therapeutics N.V.
When was this filing submitted?
The filing was submitted on August 15, 2025.
What is LAVA Therapeutics N.V.'s Central Index Key (CIK)?
LAVA Therapeutics N.V.'s CIK is 0001840748.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Was there a fee required for this filing?
No fee was required for this filing.
Filing Stats: 1,587 words · 6 min read · ~5 pages · Grade level 20 · Accepted 2025-08-15 16:14:52
Key Financial Figures
- $1.16 — apital of LAVA for a price per Share of $1.16 (the “ Base Price Per Share &rdqu
- $0.08 — s an additional amount of cash of up to $0.08 per Share (such amount as finally deter
Filing Documents
- tm2522230d6_defa14a.htm (DEFA14A) — 21KB
- 0001104659-25-079244.txt ( ) — 22KB
Forward-Looking Statements
Forward-Looking Statements This communication contains “forward-looking statements,” including, but not limited to, statements regarding the Company’s beliefs and expectations and statements about the proposed transaction, including the benefits of the proposed transaction; filings and approvals relating to the proposed transaction; the expected timing of the completion of the proposed transaction; the potential payment of proceeds to the Company’s shareholders, if any, pursuant to the CVR Agreement; and the ability and timing to complete the proposed transactions considering the various closing conditions and the consideration to be received by the Company under the Purchase Agreement. These statements may be identified by their use of forward-looking terminology including, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” and “would,” and similar words and expressions which are intended to identify forward-looking uncertainties that could cause actual results to differ materially from those projected, expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the possibility that various closing conditions set forth in the Purchase Agreement may not be satisfied or waived, including uncertainties as to the percentage of the Company’s shareholders tendering their shares in the Offer; the possibility that competing offers will be made; the possibility that the closing conditions might not be met; t